Zenas BioPharma, Inc.
ZBIO
$7.49
-$0.31-3.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -90.00% | -100.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.00% | -100.00% | -- | -- | -- |
| Cost of Revenue | 131.77% | 98.60% | -- | -- | -- |
| Gross Profit | -1,236.98% | -1,875.66% | -- | -- | -- |
| SG&A Expenses | 73.82% | 41.72% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 118.92% | 86.45% | -- | -- | -- |
| Operating Income | -503.70% | -522.95% | -- | -- | -- |
| Income Before Tax | -325.16% | -308.07% | -- | -- | -- |
| Income Tax Expenses | 42.52% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -322.87% | -309.03% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -322.87% | -309.03% | -- | -- | -- |
| EBIT | -503.70% | -522.95% | -- | -- | -- |
| EBITDA | -505.72% | -525.48% | -- | -- | -- |
| EPS Basic | -99.08% | -200.33% | -- | -- | -- |
| Normalized Basic EPS | -176.97% | -330.95% | -- | -- | -- |
| EPS Diluted | -95.37% | -193.87% | -- | -- | -- |
| Normalized Diluted EPS | -121.26% | -230.94% | -- | -- | -- |
| Average Basic Shares Outstanding | 761.28% | 103.14% | -- | -- | -- |
| Average Diluted Shares Outstanding | 713.41% | 91.77% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
